Biocon shares price has climbed 96.5% after the COVID-19 crash to attain an all-time high of Rs. 469 per share. The share price started slipping down and the current market price is traded at Rs. 428.15, accounts for an 8.7% decline from an all-time high.
Indian Biopharmaceutical company released their Q2’2021 results with net profit fell down by 22%, even materializing 10% growth in revenue. The fall in growth of profit was the reason for the market to push it back.
Still the current market price is higher than the value of the company as per an Intelligent/Fundamental Investor is a concern. We will be taking you all through a deeper analysis of the company in both Qualitative fundamental analysis. The quantitative fundamental analysis will be shared in the next article
By end of this module, you will be clear,
- Why you should invest?
- When you should invest?
- What will be the long-term benefits?
Have a look at the review of Godrej consumer product share price.
HISTORY OF BIOCON SHARES PRICE:
- Back in 1978, the biopharma company launched by India Women entrepreneur Kiran Mazumdar-Shaw. She made a joint venture with Biocon Biochemicals Limited of Ireland.
- The business kick-off by the manufacture and export enzymes to the USA and Europe. In 1989 Unilever plc acquired Ireland’s Biocon Biochemicals limited and merged it with its subsidiary Quest International.
- In this situation, the company received monetary fundings from a US company to develop their technologies in the same year. The next year (1990) the company has started its own in-house research program on solid substrate fermentation technology from pilot to plant level.
- During 1993, the company received ISO 9001 certification from RWTUV, Germany. By 1994, they launched a custom research company (CRC) named Syngene International Pvt. They lead them to a landmark of outsourcing R&D for many pharmaceutical companies inside and outside India.
- In the year 1997, the company made itself ready to launch human healthcare manufacturing facilities. The same year, Biocon becomes completely Independent, Unilever sold all the specialty chemicals shareholdings in Quest to Biocon.
- They were completely competent in setup India’s first Clinical Research Organisation (CRO) in the year for research and development on clinical studies.
- During the year 2001, they got the USFDA approval for the manufacture of Lovastatin. They were the first to receive approval in India for this cholesterol-lowering drug, Lovastatin.
- In the year 2004, they become a public company but listing in Stock markets by IPO. The IPO was a successful opening at $1 Billion market share on a listing day.
- Later in the year 2004, the company Sygene launched a new research center “INSUGEN”, a new generation bio human insulin.
- In the year 2009, launched basalog – long-acting basal insulin for both Type 1 & Type 2 insulins.
- During the year 2012, Biocon launched the positive result of a global phase 3 on recombinant human insulin.
- USFDA approved the Biologics License Application (BLA) of Biocon and Mylan on Trastuzumab – An anti-cancer drug.
- In 2019, they have launched Trastuzumab in the market for the benefit of patients in India, prior to which they launched Insulin Glargine, Bevacizumab, Itolizumab.
Have a look at our review on Discounted Cash Flow Analysis
BUSINESS OVERVIEW – BIOCON SHARES PRICE:
An Indian Multinational biopharmaceutical company that has changed many patients living in the last 4 decades. They have a presence in over 120 countries globally with their expertise in the areas like,
- Auto-Immune Disease.
The important driver of the company is to provide quality and high demand medicines at an affordable price to patients over the globe. They completely focus on four segments of the pharmaceutical business,
- Research Services
- Novel Biologics
- Touched the landmark of 2000 Cr annual revenue in FY2019-20.
- Entered into China market by 3 generic molecules and their licenses.
- Filed new drug application for various APIs
- To enhance more production on fermentation-based manufacturing site in Andhra Pradesh. This will be supplying demands for the domestic API market.
- The biologics, generally known as Biosimilars have touched almost 2.1 million patients.
- Initiated value unlocking of Biocon Biologics through private equity investment for a minority stake, indicating an equity valuation of USD 3 billion.
- Expanded various biologics globally,
- Pegfilgrastim – Australia, Canada.
- Trastuzumab – USA, Australia, Canada.
- Insulin Glargine – Australia.
- Got regulatory clearance from the USA and UK for stationing a manufacturing site for Insulin Glargine in Malaysia.
- Integrated R&D facility for 60000 sq. ft in Chennai, Tamil Nadu. This is one of the world-class integrated R&D centers available in India.
- Increased production of drug substances and drug products for key biosimilars through brownfield and greenfield projects.
- Inaugurated new facilities for research services in Hyderabad and Bengaluru.
- The API manufacturing site has newly launched in Mangalore.
- Extended biologics discovery and preclinical research capabilities in CAR-T therapy, an innovative cell-based approach to treating cancer.
- Received Good Laboratory Practice (GLP) certification for a viral testing facility from the NGCMA, making it India’s first and only GLP certified viral clearance study service provider.
- Repurposed a high-end laboratory to conduct RT-PCR tests for COVID-19.
- Partnered with Pune-based Mylab to supply reagents for use in its indigenously developed COVID-19 testing kits.
- Started global clinical trials for our first-in-class oral insulin molecule, Insulin Tregopil, in Type 1 diabetes.
- Clinical trials initiated by partner Equillium to study our novel anti-CD6 molecule, Itolizumab, in Lupus Nephritis and severe Asthma.
- Started a clinical trial in India to study Itolizumab in treating moderate to severe patients with COVID-19 complications.
BUSINESS REVENUE – BIOCON SHARES PRICE:
The above image are the snap of business revenue for the financial year 2019-20.
The consolidated revenue of all segments together was Rs. 6528.6 Cr with a growth of 15% over the last financial year. In which the split are as,
- Generics – 31%
- Biologics – 29%
- Research Services – 30%
- Novel Molecules – 8%
- Others – 2%
When we considered the demographics in revenue split. 22% of revenue comes from domestic business and 78% are dominated by global business.
The company has invested almost 10% of total revenue in research and development.
KEY STRATEGY PRIORITIES:
- Building a robust portfolio
- Forward integrate based on strength in APIs.
- Develop Complex Formulations.
- Current API Portfolios
- Multiple Sclerosis
- Sustaining the base business.
- Expanding manufacturing base.
- Cost Improvement Initiatives.
- Expanding Commercial footprint
- Strenghtening quality Systems
- people Development.
PIPELINES OF PRODUCTS:
- Insulin Tregopil – first-in-class oral prandial insulin molecule for post-prandial glycaemic control
- FmAb2 – Biocon’s immuno-oncology program focusing on development of novel bi-functional fusion antibodies
- Itolizumab – ALZUMAb™ (Itolizumab), our novel biologic, launched in India for the treatment of chronic plaque psoriasis
Hereby, we conclude the qualitative fundamental analysis of the company. In the next article we will be taking through the quantitative fundamental analysis.
Happy Learning and Investing!!